SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Edna Strauss, Francisco Augusto Porto-Ferreira, Cesar de Almeida-Neto, Maria Cristina Dias Teixeira, Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself, Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 1, 40

    CrossRef

  2. 2
    B. H. Mullish, M. S. Kabir, M. R. Thursz, A. Dhar, Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation, Alimentary Pharmacology & Therapeutics, 2014, 40, 8
  3. 3
    Andreas Baranyi, Andreas Meinitzer, Alexandra Stepan, Csilla Putz-Bankuti, Robert J. Breitenecker, Rudolf Stauber, Hans-Peter Kapfhammer, Hans-Bernd Rothenhäusler, A Biopsychosocial Model of Interferon-Alpha-Induced Depression in Patients with Chronic Hepatitis C Infection, Psychotherapy and Psychosomatics, 2013, 82, 5, 332

    CrossRef

  4. 4
    Chia-Jung Lee, Chen-Hung Cheng, Yu-Hsien Li, Chia-Yu Liu, Chung-Hua Hsu, A Chinese Medicine, Kuan-Sin-Yin Decoction, Improves Liver Function in Hepatitis B Virus Carriers: A Randomized, Controlled Study, The Journal of Alternative and Complementary Medicine, 2013, 19, 12, 964

    CrossRef

  5. 5
    Jianqian Chao, Long Song, Hua Zhang, Liguo Zhu, Lin Tian, Hui Jin, Pei Liu, Effects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China, BMC Health Services Research, 2013, 13, 1, 386

    CrossRef

  6. 6
    Bruno Cópio Fábregas, Renata Eliane de Ávila, Marjore Novaes Faria, Alexandre Sampaio Moura, Ricardo Andrade Carmo, Antonio Lúcio Teixeira, Health related quality of life among patients with chronic hepatitis C: a cross-sectional study of sociodemographic, psychopathological and psychiatric determinants, The Brazilian Journal of Infectious Diseases, 2013, 17, 6, 633

    CrossRef

  7. 7
    Elisabetta Degasperi, Mauro Viganò, Alessio Aghemo, Pietro Lampertico, Massimo Colombo, PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history, Expert Review of Anti-infective Therapy, 2013, 11, 5, 459

    CrossRef

  8. 8
    Gülseren Keskin, Aysun Babacan Gümüs, Fatma Orgun, Quality of Life, Depression, and Anxiety Among Hepatitis B Patients, Gastroenterology Nursing, 2013, 36, 5, 346

    CrossRef

  9. You have free access to this content9
    Geoffrey Dusheiko, Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues, Liver International, 2013, 33,
  10. You have free access to this content10
    Pietro Lampertico, Mauro Viganò, Massimo Colombo, Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?, Liver International, 2013, 33,
  11. 11
    Dilip Ratnam, Anouk Dev, Tin Nguyen, Vijaya Sundararajan, Hugh Harley, Wendy Cheng, Alice Lee, Ferry Rusli, Robert Chen, Sally Bell, Stephen Pianko, William Sievert, Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: A multicenter clinical experience, Journal of Gastroenterology and Hepatology, 2012, 27, 9
  12. 12
    Martin Schaefer, Lucile Capuron, Astrid Friebe, Crisanto Diez-Quevedo, Geert Robaeys, Sergio Neri, Graham R. Foster, Achim Kautz, Daniel Forton, Carmine M. Pariante, Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement, Journal of Hepatology, 2012, 57, 6, 1379

    CrossRef

  13. 13
    Changhua Ji, Konduru S.R. Sastry, Georg Tiefenthaler, Jennifer Cano, Tenny Tang, Zi Zong Ho, Denise Teoh, Sandhya Bohini, Antony Chen, Surya Sankuratri, Paul A. Macary, Patrick Kennedy, Han Ma, Stefan Ries, Klaus Klumpp, Erhard Kopetzki, Antonio Bertoletti, Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies, Hepatology, 2012, 56, 6
  14. 14
    Sener BARUT, Jale YUKSEK, Engin SEZER, Ozgur GUNAL, Dogan KOSEOGLU, Morbilliform drug eruption due to pegylated α-interferon can show complete regression after switching to non-pegylated interferon, The Journal of Dermatology, 2011, 38, 5
  15. 15
    Jeng-Fu Yang, Yi-Hui Kao, Chia-Yen Dai, Jee-Fu Huang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wan-Long Chuang, Ming-Lung Yu, Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan, Hepatology International, 2010, 4, 4, 732

    CrossRef

  16. 16
    Hui-Hui Tan, Paul Martin, Management of End-Stage Liver Disease in Chronic Hepatitis B, Clinics in Liver Disease, 2010, 14, 3, 477

    CrossRef

  17. 17
    R. B. Takkenberg, C. J. Weegink, H. L. Zaaijer, H. W. Reesink, New developments in antiviral therapy for chronic hepatitis B, Vox Sanguinis, 2010, 98, 4
  18. 18
    Irene Ray, Deep Dutta, Pallavi Basu, Binay K. De, Quality of life assessment of patients with chronic liver disease in eastern India using a Bengali translation chronic liver disease questionnaire, Indian Journal of Gastroenterology, 2010, 29, 5, 187

    CrossRef

  19. 19
    Robert Perrillo, Benefits and risks of interferon therapy for hepatitis B, Hepatology, 2009, 49, S5
  20. 20
    Jules L. Dienstag, Benefits and risks of nucleoside analog therapy for hepatitis B, Hepatology, 2009, 49, S5
  21. 21
    Gillian M. Keating, Peginterferon-α-2a (40 kD), Drugs, 2009, 69, 18, 2633

    CrossRef

  22. 22
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2008, 17, 9
  23. 23
    Peter Ferenci, Katharina Staufer, Depression in chronic hepatitis: the virus, the drug, or the ethnic background?, Liver International, 2008, 28, 4